Analyst Team

Robert M. Wasserman, Director of Research

Mr. Wasserman has over twenty five years of experience in equity research, specializing in the area of health care with a unique focus on companies in the Southeastern US and Florida . Among the areas Mr. Wasserman has covered are pharmaceuticals, medical devices, healthcare services and biotechnology. Mr. Wasserman has analyzed and written on over 100 publicly traded health care companies. Mr. Wasserman was the founder of the Research effort at Dawson James, and he has also served as Director of Research for Jesup & Lamont, Senior Research Analyst for Craig-Hallum Capital Group and Vice President-Research and Partner for Southeast Research Partners/Ryan Beck. Prior to entering the securities industry, Mr. Wasserman was a management consultant with Peat, Marwick, Mitchell & Co., now KPMG Peat Marwick.

Mr. Wasserman was selected All-Star Healthcare analyst for 2000 by the Wall Street Journal, and has appeared in a number of media outlets, including Business Week, Forbes, The New York Times and CNBC.

Mr. Wasserman received his Masters of Business Administration degree in Finance from the University of Chicago and dual Bachelor of Science degrees in Management and Engineering from the Massachusetts Institute of Technology.


Jason Kolbert, Managing Director, Head of Healthcare Research

Jason’s career began as a chemist in the pharmaceutical industry and evolved into a product and marketing manager with Schering-Plough in Japan. Upon returning from Japan, Jason joined Salomon Smith Barney, as a research associate which has now evolved into a 20-year career on Wall Street as a leader in the Healthcare space.

Jason will leverage his unique and diversified experiences to work across the Dawson James platform to augment the research product focusing on small and middle capitalized emerging growth companies utilizing Dawson James’ “Diversified Investor Offering™”, building their shareholder base with a combination of retail and institutional accounts.

Jason’s coverage will be across multiple therapeutic areas in biotechnology, specialty pharmaceuticals, and medical devices. As an analyst Jason has developed a high level of expertise in oncology, virology and cell-based medicine such as CAR (Chimeric Antigen Receptor)-T cells and regenerative medicine (stem cells).

Mr. Kolbert spent the last year as a senior biotechnology analyst at HC Wainwright and previously seven years at the Maxim group, where he was an Executive Managing Director and the Head of Healthcare at the firm. During this period Jason and his team covered 80 names across the healthcare vertical. Jason’s Wall Street career began with seven years at Citi Group followed by several years on the buy side as a portfolio manager with the Susquehanna International Group. Mr. Kolbert returned to his sell-side role after spending time in Industry as the head of business development for a public cell therapy company. Mr. Kolbert holds an undergraduate degree from the State University of New York in Chemistry and a Master’s in Business Administration from the University of New Haven.